Company Description
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally.
The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis.
The company distributes its products through third-party distributors. It has collaborations with F.
Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
| Country | United States |
| Founded | 1998 |
| IPO Date | Jun 20, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 995 |
| CEO | Dr. Matthew B. Klein F.A.C.S., M.D., M.S. |
Contact Details
Address: 500 Warren Corporate Center Drive Warren, New Jersey 07059 United States | |
| Phone | (908) 222-7000 |
| Website | ptcbio.com |
Stock Details
| Ticker Symbol | PTCT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001070081 |
| CUSIP Number | 69366J200 |
| ISIN Number | US69366J2006 |
| Employer ID | 04-3416587 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Matthew B. Klein F.A.C.S., M.D., M.S. | Chief Executive Officer and Director |
| Dr. Stuart W. Peltz Ph.D. | Co-Founder, Senior Consultant and Member of Scientific Advisory Board |
| Dr. Allan Steven Jacobson Ph.D. | Co-Founder, Chairman of Scientific Advisory Board and Independent Director |
| Dr. Neil Almstead Ph.D. | Chief Technical Operations Officer |
| Eric Pauwels | Chief Business Officer |
| Pierre Gravier M.S. | Chief Financial Officer |
| Christine Utter | Senior Vice President, Chief Accounting Officer and Head of People Services |
| Alex Kane | Investor Relations Officer |
| Mark Elliott Boulding | Executive Vice President and Chief Legal Officer |
| Jane Baj | Vice President of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | 144 | Filing |
| Apr 17, 2024 | 144 | Filing |
| Apr 17, 2024 | 144 | Filing |
| Apr 2, 2024 | 144 | Filing |
| Feb 29, 2024 | 10-K | Annual Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |